CFO
INDV icon

CVA Family Office’s Indivior Pharmaceuticals INDV Stock Holding History

CVA Family Office’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63K Buy
64
+32
+100% +$1.16K ﹤0.01% 1465
2026
Q1 		$975 Buy
+32
New +$1.06K ﹤0.01% 1657
2024
Q4 		– Sell
-204
Closed -$1.99K – 1315
2024
Q3 		$1.99K Buy
204
+74
+57% +$867 ﹤0.01% 981
2024
Q2 		$2.1K Hold
130
– – ﹤0.01% 951
2024
Q1 		$2.79K Buy
+130
New +$2.44K ﹤0.01% 895

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CVA Family Office's INDV Position: Q2 2026 in Review

CVA Family Office increased its Indivior Pharmaceuticals (INDV) stake by 100% in Q2 2026, buying an estimated $1.16K and bringing the position to 64 shares worth $2.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

CVA Family Office first reported a position in INDV in Q1 2024 and has held it in 5 quarters since. The position peaked at $2.79K in Q1 2024. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • CVA Family Office held 64 shares of Indivior Pharmaceuticals worth $2.63K as of Q2 2026.
  • CVA Family Office bought 32 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.16K.
  • Indivior Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1465 holding.
  • CVA Family Office first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • CVA Family Office's Indivior Pharmaceuticals position peaked at $2.79K in Q1 2024.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.